Schedule

Agenda

Magenta

Stay updated on platform news and potential beta tests.

Regular

Join us at Cure on January 31 to hear from experts about prospects for exits in the coming year, and how to strategize what flavor of exit would be right for your company—an IPO, M&A, JV, or something else.

This exciting initiative is set to make a significant impact on the startup ecosystem, offering valuable opportunities for growth and innovation. 

The Xchange prize for startups is up and running!

Seema Kumar 

Antitrust Partner at Herrington & Sutcliffe LLP

Anna Aryankalayil, JD

Partner at Orrick, Herrington & Sutcliffe LLP

Albert Vanderlaan, JD

Partner, Head of Americas Equity Capital Markets, Goldman Sachs

Gabe Gelman

Co-Chair of the Life Sciences Group, Orrick, Herrington & Sutcliffe LLP

Stephen Thau, JD

We focus on serving the Technology & Innovation, Energy & Infrastructure and Finance sectors globally. Clients worldwide call on our teams for forward-looking commercial advice on transactions, litigation and compliance matters. We bring distinctive quality, teamwork and value to the table – and innovate in everything we do.

Will IPOs Return in 2024?